Benefits of cardiac resynchronization therapy
This article has no abstract so we have provided the first paragraph of the full text.
Results from the Cardiac Resynchronization—Heart Failure (CARE-HF) study support the use of implantable cardiac-resynchronization devices in patients with heart failure due to left-ventricular systolic dysfunction and cardiac dyssynchrony. As anticipated, symptoms, left-ventricular function and quality of life improved, and plasma concentrations of natriuretic peptides declined in patients receiving this intervention. Importantly, the trial also revealed that these benefits were accompanied by a substantial reduction in the risk of death or complications.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
